Stockscreener 앱 받기
32.71
2.12%
-0.71
시간 외 거래:
32.50
-0.21
-0.64%
전일 마감가:
$33.42
열려 있는:
$33.8
하루 거래량:
50,382
Relative Volume:
0.97
시가총액:
$224.63M
수익:
-
순이익/손실:
$-4.98M
주가수익비율:
-24.82
EPS:
-1.3177
순현금흐름:
$-3.85M
1주 성능:
-1.21%
1개월 성능:
-9.11%
6개월 성능:
-33.16%
1년 성능:
+2,901%
1일 변동 폭
$32.00
$33.82
1주일 범위
$31.10
$35.94
52주 변동 폭
$0.93
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
DRUG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
32.71 | 224.63M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 개시 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | Robert W. Baird | Outperform |
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Uncover the Best-Performing Canadian Biotech Stocks of 2025 - Investing News Network
When (DRUG) Moves Investors should Listen - news.stocktradersdaily.com
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (NASDAQ:DRUG) - Seeking Alpha
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Discover the Top 5 Small-Cap Biotech Stocks in 2025 - Investing News Network
(DRUG) Trading Advice - news.stocktradersdaily.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Decrease in Short Interest - Defense World
DRUG FY2025 EPS Estimate Decreased by Cantor Fitzgerald - The AM Reporter
Cantor Fitzgerald Has Weak Forecast for DRUG FY2025 Earnings - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 0.8% – Here’s Why - Defense World
Bright Minds Biosciences Independent Director Nils Bottler Sells 100% Of Holding - simplywall.st
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research - GlobeNewswire
Bright Minds Biosciences Strengthens Epilepsy Focus with New Advisory Board Members - TipRanks
Can These 5 Epilepsy Experts Accelerate Bright Minds' Breakthrough Drug Development? - StockTitan
DRUGBright Minds Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March - The Manila Times
Can This CNS Drug Developer's Triple Conference Tour Spark Investor Interest? - StockTitan
How the (DRUG) price action is used to our Advantage - news.stocktradersdaily.com
HC Wainwright Issues Negative Estimate for DRUG Earnings - Defense World
H.C. Wainwright maintains $85 target on Bright Minds stock By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains $85 target on Bright Minds stock - Investing.com India
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences’ BMB-101: A Promising Contender in Serotonergic Epilepsy Treatment with Strong Market Potential - TipRanks
Bright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPS - MarketBeat
Bright Minds Biosciences Dramatic Surge Highlights the High-Stakes Nature of Biotech Investments - HPBL
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - Benzinga
Bright Minds Biosciences Shows Financial Improvement in Latest Report - TipRanks
SEC Form F-3 filed by Bright Minds Biosciences Inc. - Quantisnow
More Money In The Bank For Bright Minds Biosciences Insiders Who Divested CA$16m - Simply Wall St
How To Buy Bright Minds Biosciences Inc. Stock Online in February 2025 - Traders Union
Long Term Trading Analysis for (DRUG) - Stock Traders Daily
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 - Seeking Alpha
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Piper Sandler - Defense World
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Piper Sandler sets $93 target for Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Predicts DRUG FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DRUG FY2025 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler - MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Learn to Evaluate (DRUG) using the Charts - Stock Traders Daily
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics - MSN
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Cantor Fitzgerald Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
HC Wainwright Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences Inc (DRUG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):